KDF1 Human Pre-designed siRNA Set A

Cat. No.: K1479622

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

KDF1 Human Pre-designed siRNA Set A contains three designed siRNAs for KDF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components KDF1 siRNA-1: 5 nmol (HPLC) KDF1 siRNA-2: 5 nmol (HPLC) KDF1 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Product Line

Prodotti biologici

Application Protocols

Item-specific facts (from Product Data only)

• Manufacturer-tested applications, recommended transfection conditions, working concentrations, and positive-control references: Not specified for this item; refer to CoA/Spec Sheet.

General suggestion

• Follow your laboratory’s standard operating procedures for siRNA transfection and validation. Refer to the SDS and the product’s CoA/Spec Sheet for any item-specific instructions when available.

Biological Roles

Item-specific facts (from Product Data)

• Target: Human KDF1 (Keratinocyte Differentiation Factor 1). Additional biological details Not specified for this item; refer to CoA/Spec Sheet.

General/literature background on KDF1 (not item-specific; for context)

• KDF1 is implicated in epidermal/keratinocyte differentiation programs and skin barrier formation. Genetic studies have associated perturbations of KDF1 with defects in epidermal stratification and hair follicle development.
• At the cellular level, KDF1 has been reported to modulate pathways governing proliferation–differentiation balance in keratinocytes, influencing expression of structural keratins and late differentiation markers.
• Functional interrogation via siRNA-mediated knockdown enables temporal dissection of KDF1’s role in lineage commitment, cytoskeletal organization, and cell–cell adhesion pathways.

Research implications

• Combining siRNA knockdown with transcriptomic or proteomic profiling can uncover KDF1-dependent regulatory networks.
• Phenotypic assays may include changes in keratin expression, stratification markers, and barrier-related gene sets in epithelial cell models.

Note

• The above content is provided as general biological background. No performance or application claims are made for this specific product beyond research use only.

Buffer Applications

Item-specific facts (from Product Data)

• No buffer formulation or pH specifications are provided for this item; refer to CoA/Spec Sheet.

General guidance for siRNA handling buffers (not item-specific)

• Reconstitution: RNase-free water or 10 mM Tris-HCl, pH 7.5–8.0; optional 0.1–1 mM EDTA (TE) to enhance stability by chelating Mg2+.
• Working stocks: 10–50 µM commonly used; prepare aliquots to avoid freeze–thaw cycles. Filter-sterilized, nuclease-free solutions are recommended.
• Storage buffer: Slightly basic pH (7.5–8.0) favors stability relative to acidic conditions; avoid strong alkaline pH which accelerates RNA backbone cleavage.
• Compatibility: For complex formation with cationic lipids/polymers, salt-free water may be preferred; verify reagent guidelines. Avoid heparin or polyanions that disrupt complexes.

Electrophoresis/analysis (general)

• Native PAGE or agarose with appropriate dyes (e.g., SYBR Gold) can assess duplex integrity; run in RNase-free TBE or TBE–urea (for denaturing analysis).

Green Alternatives

Context

• This product is an aqueous, nucleic acid–based research reagent; organic solvent use arises mainly from downstream transfection formulations.

Greener practice considerations (general; not item-specific)

• Use aqueous reconstitution (RNase-free water or TE) and avoid organic co-solvents.
• Prefer low-toxicity, biodegradable transfection reagents where effective; screen peptide- or polymer-based systems that permit reduced dosing.
• Minimize plastic consumables through careful planning and aliquoting; select RNase-free, recyclable plastics when available.
• Consolidate experiments to reduce reagent shipping frequency. Lyophilized formats (if offered) can support ambient shipment, reducing cold-chain impact—Not specified for this item; refer to CoA/Spec Sheet.

Comparison (general)

• Conventional cationic lipids: High efficiency but may have higher cytotoxicity and environmental persistence.
• Next-gen biodegradable lipids/polymers: Lower persistence; may require optimization to match efficiency.
• Electroporation: Solvent-free delivery; increased power consumption and potential cell stress—trade-offs should be considered.

Waste reduction

• Prepare concentrated stocks, aliquot to minimize freeze–thaw, and use RNase-free water to avoid buffer disposal. Follow local guidelines for disposal of nucleic acid waste and contaminated materials.

Pharmaceutical Uses

Item-specific facts (from Product Data)

• No pharmacopeial grade or formulation status specified. For research use only; not for human or veterinary use.

General context (not item-specific)

• In pharmaceutical R&D settings, siRNA reagents are utilized for target validation, pathway deconvolution, and mechanism-of-action studies in discovery programs.
• Formulation excipient interactions are relevant in research prototypes: cationic/ionizable lipids, biodegradable polymers, peptides, or conjugates (e.g., GalNAc) can influence cellular uptake and stability. Such systems are for exploratory research unless manufactured under appropriate quality systems.
• Process considerations: Endotoxin and residual solvent levels are critical for in vivo research applications; for this catalog product, such specifications are Not specified for this item; refer to CoA/Spec Sheet.

Regulatory note

• Any clinical or preclinical use requires materials produced under suitable quality frameworks (e.g., GMP) with full characterization. This product is not supplied for clinical administration.

Physical Properties

Item-specific facts (from Product Data)

• Physical state/appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight (per duplex or strand): Not specified for this item; refer to CoA/Spec Sheet.
• Extinction coefficient (ε260): Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Expected to be water-soluble; exact solubility Not specified for this item.

General/literature values and notes (not item-specific)

• siRNA oligonucleotides are highly soluble in RNase-free water and common low-ionic-strength buffers (e.g., 10 mM Tris-HCl, pH 7.5–8.0) to at least 100 µM; higher concentrations (up to mM) are feasible depending on length and modifications.
• UV absorbance: RNA absorbs strongly at 260 nm; concentration can be estimated by A260 using duplex-specific ε values when sequences are known.
• pH stability: Duplex RNA is generally stable around neutral pH; hydrolysis accelerates under strong alkaline conditions.
• Thermal properties: siRNA melting temperatures (Tm) often lie between 55–80°C depending on sequence, salt, and modifications; exact Tm for this product is Not specified for this item.

Practical implications

• Prepare and store solutions in RNase-free conditions to preserve integrity; avoid repeated freeze–thaw cycles which can promote strand scission or adsorption losses.
• If lyophilized, reconstitution volumes should be chosen to achieve desired working stocks (e.g., 10–50 µM), but exact guidance is sequence- and application-dependent.

Quality and Grades

Item-specific facts (from Product Data)

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

Interpretive guidance (general; not item-specific)

• Oligonucleotide “purity” may refer to desalting only, cartridge purification, HPLC, or PAGE. Higher-purity siRNA (e.g., HPLC) reduces truncated sequences and can improve knockdown consistency, especially at lower doses or for sensitive applications.
• Modification profile (e.g., 2′-O-methyl, 2′-F, phosphorothioate linkages) can enhance nuclease resistance and reduce innate immune activation; such features, if present, should be listed on the CoA/Spec Sheet.
• Quantitation may be reported as OD260 units, nmol, or µg; conversion depends on sequence and extinction coefficients.
• Identity confirmation typically involves LC–MS (intact mass), capillary electrophoresis or HPLC for purity, and, where applicable, sequence verification by MS/MS or enzymatic mapping.

What to check on receipt

• Verify number of duplexes in “Set A,” individual target sites, sense/antisense sequences, modification status, scale (nmol), and recommended reconstitution concentration—Not specified for this item; refer to CoA/Spec Sheet.
• Confirm recommended application notes and any performance validation data (e.g., knockdown percentages in reference cell lines), if provided by the manufacturer.

Reaction and Applications

Item-specific facts (from Product Data)

• Application note: Not provided. Product is a pre-designed siRNA set targeting human KDF1 (research use only).

General applications for siRNA (not item-specific)

• Gene silencing: Transient knockdown of KDF1 mRNA to study gene function, pathway interactions, and phenotypes in human cell models.
• Screening: Parallel testing of multiple duplexes to identify the most potent/least off-target guide; combine with qPCR or RNA-seq for transcript quantification.
• Mechanistic studies: Dissect KDF1’s role in keratinocyte differentiation and epidermal development by assessing downstream markers upon knockdown.
• Rescue experiments: Validate on-target effects by expressing an siRNA-resistant KDF1 cDNA.

Practical tips (general)

• Use multiple independent siRNA duplexes and include non-targeting and positive-control siRNA controls.
• Optimize transfection: cell confluence (typically 50–80%), siRNA:reagent ratios, and exposure time. Assess cytotoxicity separately from knockdown efficacy.
• Quantify knockdown at 24–72 h for mRNA (qPCR) and 48–96 h for protein (immunoblot/IF), depending on KDF1 protein turnover.
• Minimize off-targets: Use the lowest effective siRNA dose (e.g., 5–20 nM), pool top-performing duplexes, and avoid seed-region homology to unrelated transcripts (design-level consideration for pre-designed sets).

Reaction Conditions

Interpretation for this reagent type

• “Reaction” is understood here as cellular transfection and RISC-mediated silencing rather than a chemical transformation.

General/literature conditions for siRNA transfection (not item-specific)

• Cell health and density: Seed to reach 50–80% confluence at transfection.
• Dose: Start with 5–20 nM siRNA; titrate to minimize off-targets while achieving knockdown.
• Complexation: Follow transfection reagent guidelines; pre-incubate siRNA with lipid/polymer (typically 5–20 min at room temperature) in serum-free medium, then add to cells; replace with complete medium after 4–24 h if required by the reagent.
• Time course: Assess mRNA reduction at 24–72 h; protein knockdown at 48–96 h depending on turnover.
• Controls: Non-targeting siRNA, positive-control siRNA, and (optionally) siRNA-resistant expression constructs for rescue.
• Readouts: qPCR for KDF1 transcript, immunoblot/IF for protein, and phenotypic assays relevant to keratinocyte differentiation.

Notes

• Exact, product-specific conditions, sequences, and recommended cell lines are Not specified for this item; refer to CoA/Spec Sheet.
• RNase-free technique and gentle handling minimize degradation and preserve activity.

Safety and Handling

Item-specific facts (from Product Data)

• GHS signal word, hazard statements, pictograms, and classification: Not specified for this item; refer to SDS.
• Research use note: For research use only.

General guidance (not item-specific; defer to SDS)

• siRNA oligonucleotides are not typically classified as hazardous chemicals; nonetheless, handle using good laboratory hygiene and appropriate PPE (lab coat, gloves, safety glasses). Avoid ingestion, inhalation of dried powders/aerosols, or contact with eyes/skin.
• Use RNase-free technique to prevent degradation: RNase-free tubes/tips, clean work surfaces, and, when appropriate, dedicated RNA work areas.
• Avoid contamination with microbial nucleases; keep solutions cold during handling and minimize bench time.
• Incompatibilities: Strong acids/bases and nucleases (RNase) will degrade RNA. Avoid prolonged exposure to elevated temperatures and UV light.
• First aid (general): In case of skin/eye contact, rinse with water. If inhaled (powder/aerosol), move to fresh air. If swallowed, rinse mouth. Seek medical attention if irritation persists. Always consult the SDS for authoritative instructions.
• Waste: Dispose of unused material and contaminated disposables as laboratory chemical/biological waste per institutional and local regulations.

Transport and storage considerations

• Shipped in an ice chest with ice pads (per Product Data). Maintain cold chain on receipt and transfer promptly to the recommended storage.

Solvent Selection

Item-specific facts (from Product Data)

• No specific solvent recommendations provided; storage at −20°C. Reconstitution details Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance for siRNA (not item-specific)

• Primary solvent: RNase-free water is the default for initial reconstitution. For improved stability, low-ionic-strength buffers such as 10 mM Tris-HCl, pH 7.5–8.0 with 0.1–1 mM EDTA (TE) are routinely used to chelate divalent cations that catalyze RNA degradation.
• Avoid: Strongly alkaline buffers (promote transesterification) and repeated freeze–thaw in dilute solutions. Do not use phenol/chloroform or alcohols for routine dissolution; these are used for extraction, not storage.
• Working solutions: Maintain in aqueous buffers compatible with transfection reagents and cells; high salt or divalent cations can interfere with complexation.

Comparison (general)

• RNase-free water: maximal compatibility, minimal components; slightly less protective against hydrolysis/metal-catalyzed cleavage.
• TE buffer (10 mM Tris, 0.1–1 mM EDTA): enhanced stability; confirm compatibility with downstream transfection (some lipofection reagents recommend salt-free water for complex formation).
• PBS: generally avoided for stock prep due to ionic strength; small carryover into culture is typically tolerated but follow reagent-specific guidance.

Storage and Reconstitution

Item-specific facts (from Product Data)

• Storage conditions: Store at −20°C.
• Shipping: Ice chest with ice pads.

General/literature guidance (not item-specific)

• If lyophilized: Centrifuge briefly to collect material at the bottom before opening. Reconstitute in RNase-free water or 10 mM Tris-HCl, pH 7.5–8.0 (optional 0.1–1 mM EDTA). Prepare concentrated stocks (e.g., 10–50 µM) and aliquot into RNase-free tubes to avoid repeated freeze–thaw.
• If supplied in solution: Keep at −20°C for long-term storage. For frequent use, maintain working aliquots at −20°C and avoid multiple freeze–thaw cycles.
• Handling: Work on ice when possible. Use RNase-free consumables. Avoid prolonged exposure to room temperature and direct light.
• Stability expectations: Duplex siRNA is generally stable for months at −20°C and for days to weeks at 4°C depending on buffer and modifications; exact stability for this item is Not specified for this item; refer to CoA/Spec Sheet.
• Thawing: Thaw on ice, mix gently by pipetting or brief low-speed vortex, and quick spin to collect. Do not heat above room temperature unless specified.

Documentation

• For exact reconstitution volumes, concentration calculations (OD260 to nmol), and any modification-specific recommendations, refer to the CoA/Spec Sheet.

Structure and Identity

Item-specific facts (from Product Data)

• Product: KDF1 Human Pre-designed siRNA Set A (SKU: K1479622)
• Type: Pre-designed small interfering RNA (siRNA) reagent set targeting human KDF1
• CAS: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES / InChIKey: Not applicable to heterogeneous oligonucleotide sets; not specified for this item.

General/literature description (not item-specific)

• siRNA are short double-stranded RNA duplexes (typically 19–21 bp) with characteristic 2-nt 3′ overhangs that guide RISC-mediated cleavage of complementary mRNA.
• A “pre-designed” human siRNA set against KDF1 generally comprises multiple duplexes directed to distinct regions of the KDF1 transcript to enhance knockdown robustness and allow selection of the best-performing guide.
• 2D structural features: each duplex consists of a sense (passenger) and antisense (guide) strand with standard ribose-phosphate backbone; may include terminal 5′-phosphate/3′-hydroxyl ends and optional chemical stabilizations (e.g., 2′-O-Me, phosphorothioate) depending on manufacturer—Not specified for this item; refer to CoA/Spec Sheet.

Notes

• Sequence information, strand lengths, modifications, and exact number of duplexes in “Set A” are Not specified for this item; refer to CoA/Spec Sheet.

Synthetic Utility

Scope

• This product is a functional nucleic acid reagent, not a small-molecule building block. It is not typically used as a substrate, catalyst, or reagent in organic synthesis.

General/literature perspective (not item-specific)

• Oligonucleotides themselves are products of solid-phase synthesis (e.g., phosphoramidite chemistry). Downstream “utility” pertains to molecular biology applications—gene silencing, pathway interrogation, and validation—rather than chemical synthesis.

Guidance

• If chemical conjugation is desired (e.g., fluorophores, delivery ligands), such modifications must be specified at the time of manufacture. Modification details for this item are Not specified for this item; refer to CoA/Spec Sheet.

Target Specificity

Item-specific facts (from Product Data only)

• Target gene: KDF1 (Keratinocyte Differentiation Factor 1), Homo sapiens.
• Format: Pre-designed siRNA Set A directed against human KDF1.
• Additional details such as target site positions, guide sequences, predicted off-targets, and cross-species reactivity: Not specified for this item; refer to CoA/Spec Sheet.

Domande frequenti

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.